Randy Albelda1, Emily Wiemers2, Theresa Hahn3, Nandita Khera4, Diana Y Salas Coronado2, Gregory A Abel5. 1. University of Massachusetts Boston, Boston, MA, USA. randy.albelda@umb.edu. 2. University of Massachusetts Boston, Boston, MA, USA. 3. Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 4. Mayo Clinic Arizona, Phoenix, AZ, USA. 5. Dana Farber Cancer Institute, Boston, MA, USA.
Abstract
PURPOSE: The US does not have universal paid family and medical leave. We examine the direct effects of access to paid leave on patient-reported health, quality of life (QOL), and perceived stress of employed patients who underwent bone marrow transplantation (BMT) to treat advanced blood cancer as well as the indirect effects through reductions in the financial burden (FB) that patients face. METHODS: Our cross-sectional observational study took place at three US transplantation centers in 2014 and 2015. All English-speaking cancer patients 6-month post-BMT were mailed a 43-item survey assessing financial situation, employer benefits, and patient-reported health outcomes. The sample includes the 171 respondents who were employed at the time of BMT. RESULTS: Seemingly unrelated regression analysis confirms that patient access to paid leave was associated with reductions in all three measures of FB, and lower levels of financial hardship were related with improved health, QOL, and perceived stress outcomes. For self-reported health and perceived stress outcomes, all of the effects of patient paid leave operate indirectly through reductions in FB. For QOL outcomes, there is both a direct effect (over 80%) of paid leave and an indirect effect through reduction of FB. CONCLUSION: We found that paid leave affected health outcomes for BMT patients mostly through alleviating FB. These findings suggest universal paid leave policies in the US might alleviate financial hardship and have positive effects on the self-reported QOL of employed patients facing intensive medical treatments.
PURPOSE: The US does not have universal paid family and medical leave. We examine the direct effects of access to paid leave on patient-reported health, quality of life (QOL), and perceived stress of employed patients who underwent bone marrow transplantation (BMT) to treat advanced blood cancer as well as the indirect effects through reductions in the financial burden (FB) that patients face. METHODS: Our cross-sectional observational study took place at three US transplantation centers in 2014 and 2015. All English-speaking cancerpatients 6-month post-BMT were mailed a 43-item survey assessing financial situation, employer benefits, and patient-reported health outcomes. The sample includes the 171 respondents who were employed at the time of BMT. RESULTS: Seemingly unrelated regression analysis confirms that patient access to paid leave was associated with reductions in all three measures of FB, and lower levels of financial hardship were related with improved health, QOL, and perceived stress outcomes. For self-reported health and perceived stress outcomes, all of the effects of patient paid leave operate indirectly through reductions in FB. For QOL outcomes, there is both a direct effect (over 80%) of paid leave and an indirect effect through reduction of FB. CONCLUSION: We found that paid leave affected health outcomes for BMT patients mostly through alleviating FB. These findings suggest universal paid leave policies in the US might alleviate financial hardship and have positive effects on the self-reported QOL of employed patients facing intensive medical treatments.
Entities:
Keywords:
Bone marrow transplantation; Cancer treatment; Financial burden; Paid leave; Quality of life; United States
Authors: Jada G Hamilton; Lisa M Wu; Jane E Austin; Heiddis Valdimarsdottir; Katie Basmajian; Annamarie Vu; Scott D Rowley; Luis Isola; William H Redd; Christine Rini Journal: Psychooncology Date: 2012-05-18 Impact factor: 3.894
Authors: Erin E Kent; Laura P Forsythe; K Robin Yabroff; Kathryn E Weaver; Janet S de Moor; Juan L Rodriguez; Julia H Rowland Journal: Cancer Date: 2013-07-31 Impact factor: 6.860
Authors: Fausto R Loberiza; Stephanie J Lee; John P Klein; Anna Hassebroek; Jason G Dehn; Haydar A Frangoul; Theresa Hahn; Gregory Hale; Hillard M Lazarus; Charles F LeMaistre; Richard T Maziarz; J Douglas Rizzo; Navneet S Majhail Journal: Biol Blood Marrow Transplant Date: 2009-10-30 Impact factor: 5.742
Authors: N S Majhail; J D Rizzo; T Hahn; S J Lee; P L McCarthy; M Ammi; E Denzen; R Drexler; S Flesch; H James; N Omondi; T L Pedersen; E Murphy; K Pederson Journal: Bone Marrow Transplant Date: 2012-12-10 Impact factor: 5.483
Authors: Caitlin B Biddell; Stephanie B Wheeler; Rebekah S M Angove; Kathleen D Gallagher; Eric Anderson; Erin E Kent; Lisa P Spees Journal: Front Oncol Date: 2021-07-30 Impact factor: 6.244
Authors: Caitlin B Biddell; Kimberly A Kasow; Mary K Killela; Kristin M Page; Stephanie B Wheeler; Sarah W Drier; Matthew S Kelly; Joanna M Robles; Lisa P Spees Journal: Support Care Cancer Date: 2022-02-07 Impact factor: 3.359